The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Elahere Abbvie Pty Ltd
Product name
Elahere
Sponsor
Accepted date
Jan-2025
Active ingredients
mirvetuximab soravtansine
Proposed indication
ELAHERE is a treatment for adult patients with a specific type of ovarian, fallopian tube, or peritoneal cancer that is resistant to platinum-based chemotherapy. It is used when patients have already tried one to three other treatments.
Application type
A (new medicine)
Publication date
Jan-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.